Nordic's $62m IPO reheats anti-CD37 cancer therapies
This article was originally published in Scrip
In the biggest life science initial public offering on a European exchange since November 2014, Nordic Nanovector grossed NOK 500m ($62.3m) from its IPO on the Oslo stock exchange on 23 March 2015. The company raised 20% more than it had originally planned, allowing it now to reach comfortably beyond the first regulatory submission for its lead product Betalutin (177Lu-tetulomab) in non-Hodgkin's lymphoma (NHL). The IPO also potentially breathes new life into an old blood cancer target, CD37.
You may also be interested in...
Nordic Nanovector's oversubscribed private placing secures its freedom to target therapies for hematological cancers and compete directly with other fully funded players in the field, while remaining independent.
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.